Psychedelic Business Spotlight- March 11
This week in psychedelic business news: Small Pharma prepares big DMT studies; Health Canada approves a psilocybin PTSD study.
psilocybin
My Favorite Psychedelic Stocks: Part 1
Our resident Psychedelic Investor details five companies he thinks are in strong position to win the psychedelic medicine race.
Psychedelic Researchers Doubt Microdosing in New York Times
After a disappointing microdosing study, Dr. Michiel van Elk says the trend is “just not that interesting.”
Oklahoma House Passes Psilocybin Decriminalization Bill
Now it’s up to the state’s Senate to consider the bill decriminalizing the possession of psilocybin and authorizing research.
The Best Cities for a Psychedelic Trip, Vol. 1
These destinations give “a quick weekend trip” a whole new meaning.
Is Wall Street the Next Stop for Psychedelics? Investing in the Psychedelic Medicine Sector
Elemental Advisors Inc. CEO Tim Collins paints a picture of the past, present, and future of the psychedelics market in this guest blog.
Is There a Difference Between Tripping on LSD and Psilocybin?
A double-blinded, randomized, and placebo-controlled study compares the subjective and autonomic effects of both psychedelics.
Study Finds Psilocybin Anti-Depression Effects Last at Least One Year
A year after a Johns Hopkins psilocybin-assisted therapy study, researchers find the number of people who benefited from receiving two doses actually increased.
The Biggest Reason People in Oregon Want to Use Psilocybin
Spoiler alert: It’s not because they’re depressed.
The Road to Psychedelics Legalization
Matthew X. Lowe, Ph.D., the Research Director of Unlimited Sciences, explains why observational research is the key for eventual legalization of psychedelic drugs.
End of content
End of content